Entity

Time filter

Source Type

Xinxiang, China

Cui K.,Xinxiang Central Hospital
Chinese Journal of Oncology | Year: 2015

Objective: To investigate the expression of IFITM3 in colorectal carcinoma and its clinical significance. Methods: 213 patients with colon ademocareinoma and 214 patients with colon adenoma treated by surgery in our hospital from March 2008 to June 2010 were included in this study. The levels of IFITM3 in normal colon nucosa, adenoma, and adenocarcinoma tissues were detected by real-time PCR and immunochemistry, and its relationship with metastasis and prognosis in 213 colorectal cancer patients was analyzed. Results: The IFITM3 mRNA level in metastatic tumor group was 18. 37 ±0.61, significantly higher than that in the normal 4.49±0.69 and non-metastases groups (7.32±0.76;F = 460.380, P< 0.001). The positive rate of IFITM3 protein expression in metastatic tumor group (69.0%) was significantly higher than that in the normal ( 3.9% ) , non-melastasies groups ( 19.0%) and adenoma groups (11.3%). Our clinical analysis confirmed that the IFITM3 expression was associated with peritumoral invasion, hepatic metastases, metastases of para-colonic lymph nodes, mesocolonic lymph nodes and mesenteric root lymph nodes, omental metastasis and AJCC classification (P<0.05). Furthermore, the survival curve analysis showed that patients with lower IFITM3 level expression had a higher 5-year survival rate (88.8%) than that in the patients with higher expression ( 40.2% ,P<0.001). Conclusions: IFITM3 expression has a positive correlation with metastasis and prognosis in patients with colorectal carcinoma. Copyright © 2015 by the Chinese Medical Association. Source


Li H.,Xinxiang Central Hospital
Pakistan journal of pharmaceutical sciences | Year: 2015

This paper on analysis pathogenic bacterial distribution of central veins Catheter-related Blood-Stream infection (CRBS) and clinical features of different infection. Ninety-one patients with CRBSI were selected, to analyze and research for etiological distribution, clinical characteristics, inflammatory markers and prognosis.Among the 91 cases, 31 cases were infected by Candida, accounting for 34.1%; 31 cases were infected by Gram-negative bacilli, accounting for 34.1%; 29 cases were infected by Gram-positive cocci, accounting for 31.8%. The CRBSI clinical features of Candida and Gram-negative bacilli high fever and chills, and Gram-positive coccal` moderate fever, chills. The pathogens CRBSI inflammatory markers in these 3 groups all were increased, but, the CRBSI inflammatory reaction of Candida and Gram-negative bacilli were more severe, the CRBSI fatality rate by Candida was high (P<0.05). Candida, Gram-negative bacilli and Gram-positive cocci were all the CRBSI common pathogenic bacterium. It shall pay attention to etiology research, at the same time, it shall take empiric therapy to decrease CRBSI fatality rate based on clinical features. Source


Wu Q.,Xinxiang Central Hospital | Yao J.,Chinese PLA General Hospital
World Journal of Surgical Oncology | Year: 2013

Background: The expression status of bone morphogenetic protein 4 (BMP4) in gliomas is still unclear by now. We try to investigate the relationship between BMP4 expression and the biological behavior of gliomas in order to lay a foundation for the management of these tumors.Methods: A total of 630 patients with glioma were enrolled in the study from January 2002 to January 2008. The expression status of BMP4 in gliomas was evaluated by RT-PCR and immunohistochemistry. The relationships between BMP4 expression and clinicopathological parameters and between BMP4 expression and prognosis were also studied. Results: The expression of BMP4 in tumor tissues was significantly lower than that in the paracancer tissues at both mRNA and protein levels (P = 0.01 and 0.001, respectively). Univariate analysis showed that BMP4 expression was closely related to extent of resection, Ki-67 expression, and the WHO grade (P = 0.001, 0.001, and 0.001, respectively), but it was not related to age, sex, or the Karnofsky Performance Status (KPS) score (P = 0.099, 0.472, and 0.201, respectively). Finally, Ki-67 expression and the WHO grade were found to be related to BMP4 expression using logistic regression (P = 0.001 and 0.001, respectively). Interestingly, we found that the expression of BMP4 was significantly related to distant glioma metastasis. Cox regression analysis identified the KPS score, extent of resection, Ki-67 expression, WHO grade, and BMP4 expression as independent prognostic factors (P = 0.044, 0.010, 0.002, 0.001, and 0.001, respectively). Conclusions: BMP4 is differentially expressed in glioma patients and is closely related to the biological behavior of gliomas. BMP4 expression was found to be a strong predictor of distant metastasis and postoperative prognosis. © 2013 Wu and Yao; licensee BioMed Central Ltd. Source


Du B.,Xinxiang Central Hospital | Zhang Z.,Xinxiang Medical University | Li N.,Xinxiang Medical University
International Immunopharmacology | Year: 2014

Inflammatory responses and autophagy have been implicated in the amyloid-β (Aβ) aggregation in Alzheimer's disease (AD) due to recycling cellular waste and eliminating toxic protein aggregates. Madecassoside (Mad), a triterpenoid saponin compound, has been found to improve impaired cognitive function. However, little was known about the protection of Mad nerve cells against inflammation response and autophagy, as well as their underlying mechanism. In the present study, we investigated whether Mad could prevent Aβ25-35-induced inflammatory responses and autophagy, as well as the possible mechanism. Transmission electron microscopy results showed that Mad could significantly reduce Aβ25-35-induced autophagosomes in neural cells. Mad could also increase cell viability whereas decrease remarkably LDH leakage in Aβ25-35-induced neural cells. Both ELISA assay and western blot showed that Mad attenuated inflammatory cytokines including tumor necrosis factor (TNF)-α, interleukin (IL)-10, IL-6 and COX-2 production. Moreover, western blot results showed that Mad could block the conversion of light chain3-I (LC3-I) to light chain3-II (LC3-II), reduce Beclin-1, whereas increase anti-apoptotic protein Bcl-2 level. The levels of Beclin-1 and hVps34 in control vector-transfected NG108-15 neural cells but not in Bcl-2 transfected NG108-15 neural cells were reduced by Mad. The levels of inflammatory cytokines including TNF-α and IL-6 productions decreased significantly by the treatment with Mad. These results demonstrated that Mad protected neural cells against inflammation and autophagy induced by Aβ25-35 through the class III PI3K/Beclin-1/Bcl-2 pathway. Our findings provide evidences for the beneficial effect of Mad on the treatment of AD. © 2014 Elsevier B.V. All rights reserved. Source


Yang Z.,Xinxiang Central Hospital
Pakistan journal of pharmaceutical sciences | Year: 2015

This paper aimed to study the effect of metronidazole sustained-release film combined with minocycline hydrochloride on treating periodontitis. 138 patients with chronic periodontitis were collected and randomly divided into control group and observation group (each of 69 cases). Patients in control group were treated by using minocycline hydrochloride, while those in observation group were treated using metronidazole sustained-release film with minocycline hydrochloride, and each group with 4 weeks of treatment. Then we observed the periodontal mend matters, therapeutic effect, adverse reaction and relapse situation of patients in two groups. Results showed that compared with the prior treatment, the gingival index, dental plaque index, odontoseisis index and pocket depth of patients in two groups was significantly reduced. Moreover, the reduction range in observation group was significantly larger and the curative effect was superior to that in control group. Therefore, metronidazole sustained-release film combined minocycline hydrochloride can evidently improve patients' periodontal status, enhance drug therapeutic effect. It has less adverse reaction and low relapse rate, thus is worthy of clinical promotion. Source

Discover hidden collaborations